Sunshine Biopharma, Inc.
SBFM
$1.14
$0.032.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.73% | 41.90% | -142.24% | 50.09% | -50.09% |
| Total Depreciation and Amortization | 1.43% | -22.01% | 2.49% | 32.87% | 11.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -74.40% | -47.76% | -- |
| Change in Net Operating Assets | 152.06% | -418.36% | 157.46% | 22.30% | -9.79% |
| Cash from Operations | 55.70% | -28.22% | -122.04% | 42.85% | 24.87% |
| Capital Expenditure | -37.25% | -610.00% | 112.50% | 95.00% | -2,033.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -200.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 101.91% | -142.44% | 65.98% | 69.12% | -90.81% |
| Cash from Investing | 95.12% | -108.17% | 57.57% | 78.50% | -159.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -100.00% | 932.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 859.60% | -97.94% | 932.54% |
| Foreign Exchange rate Adjustments | -35.91% | -104.44% | 432.28% | -168.01% | 3,391.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 409.25% | -1,107.15% | 81.67% | -145.81% | 239.62% |